This Article Full Text Full Text (PDF) All Versions of this Article: 38/5/1427    most recent STROKEAHA.106.480459v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kuller, L. H. Search for Related Content PubMed PubMed Citation Articles by Kuller, L. H. Pubmed/NCBI databases Medline Plus Health Information Medicines Stroke Related Collections Compliance/Adherence Secondary prevention Cerebrovascular disease/stroke Related Article

(Stroke. 2007;38:1427.)
© 2007 American Heart Association, Inc.

Editorials

So, What’s New?

Lewis H. Kuller, MD, DrPH

From the Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pa.

Correspondence to Lewis H. Kuller, MD, DrPH, Department of Epidemiology, University of Pittsburgh, 130 North Bellefield Ave, Rm 550, Pittsburgh, PA 15213. E-mail kullerl@edc.pitt.edu

Key Words: adherence • lipids • secondary prevention

An extract of the first 250 words of the full text is provided, because this article has no abstract.

See related article, pages 1557-1564.

Does reduced medication access after a stroke increase the risk of recurrent stroke and subsequent disability? How many recurrent strokes in the population are attributable to poor control of risk factors, such as lack of treatment of elevated blood pressure (BP), high cholesterol, diabetes or the use of antiplatelet agents, etc? The article by Levine et al¹ notes that 9% or an estimated 76 000 stroke survivors in the US were unable to afford their necessary medications. The characteristics of such individuals are, as would be expected from previous studies, lower income, lack of insurance, multiple diseases requiring high cost of treatments, lack of usual source of care and lack of disposable income to pay for the drugs.

The critical question is if we could enhance adherence, would it have any effect on outcomes? The current report by Levine et al did not measure whether the lack of funds to pay for the drug therapy had any impact on the control of risk factors or whether it had any effect on the clinical outcomes of poststroke patients. However, other studies have clearly documented that adherence to drug therapies is an important component of reducing risk of disease. Most likely, levels of risk factors and adherence to therapies are the 2 critical variables that determine risk of both incident stroke and recurrent stroke.^2–7

In 2001, Qureshi reported in 1252 survivors of myocardial infarction and stroke from the National Health And Nutrition Examination Survey (NHANES) III . . . [Full Text of this Article]

Related Article:

Reduced Medication Access: A Marker for Vulnerability in US Stroke Survivors

Deborah A. Levine, Catarina I. Kiefe, George Howard, Virginia J. Howard, O. Dale Williams, and Jeroan J. Allison
Stroke 2007 38: 1557-1564. [Abstract] [Full Text] [PDF]